Shareholders of BRAIN Biotech AG approved all agenda items with a broad majority at the company's 2026 Annual General Meeting. Dr. Ursula La Cognata, managing partner of Your Biotech Experts Partnership, was elected to the Supervisory Board for a four-year term, having previously been appointed by the Darmstadt Local Court in July 2025. The detailed voting results and all other documents relating to the 2026 Annual General Meeting are available on the BRAIN Biotech AG website: https://www.brain-biotech-group.com/en/investors/annual-general-meeting/annual-general-meeting-2026/.
Supervisory Board Chairman Dr. Michael Majerus expressed confidence in the company's development opportunities, citing its successful product business, strong market position in contract research, expected revenues from monetization initiatives, pharmaceutical project licensing, and further product innovations from the BRAINBioIncubator segment. This outlook suggests potential growth avenues for investors and partners in the biotechnology sector.
CEO Adriaan Moelker reaffirmed the company's two-pillar strategy during his address to shareholders. The strategy consists of the product-oriented BRAINBiocatalysts segment, which focuses on specialty enzymes, and the research-intensive BRAINBioIncubator segment. Moelker emphasized that this approach enables the company to monetize investments, achieve scientifically based breakthroughs, and organically expand a profitable, scalable, enzyme-focused business. For business leaders in biotechnology, this dual focus represents a balanced model combining immediate revenue generation with long-term innovation.
Moelker highlighted the company's agility as a key competitive advantage, noting that BRAIN Biotech's relatively small size allows for quick and flexible responses to customer needs through short communication channels. The CEO emphasized the importance of maintaining this advantage even during future growth phases. This operational flexibility could position the company favorably against larger, less agile competitors in the rapidly evolving biotechnology market.
The company reported progress on consolidating production and sales for enzymes and food ingredients for the baking and beverage industries at its new Netherlands location. The new facility, which includes a modern baking application center, laboratory, and production areas, is nearing completion. This infrastructure development signals the company's commitment to expanding its operational capabilities and serving key industrial sectors more effectively.
BRAIN Biotech AG operates as the parent company of the BRAIN Biotech Group, which specializes in researching, developing, and producing specialty enzymes with a focus on food and life sciences industries. The group also develops microbial production strains and scalable bioprocesses for economic production of specialty enzymes and proteins, offering customized biological solutions for more sustainable products and efficient processes. For more information about the company's operations and business segments, visit: www.brain-biotech-group.com.
The company maintains fermentation facilities in the UK with additional production sites in continental Europe and the United States. In the 2024/25 fiscal year, the group generated revenue of €49.6 million with approximately 280 employees. The consolidation of voting power at the meeting reached 61.82% of share capital, including postal votes, indicating substantial shareholder engagement with the company's strategic direction.
